On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) released negotiated maximum fair prices (MFPs) for 15 high-cost Medicare Part D drugs under the Inflation Reduction Act, effective January 1, 2027. The drugs selected are single-source, high-expenditure products without generic or biosimilar competition, covering conditions like diabetes, respiratory disease, cancer, and mental health. The negotiated MFPs reflect steep discounts (38%–85%) compared to current wholesale acquisition costs, with hopes of delivering major savings for Medicare. CMS will explain pricing methodology by March 1, 2026, and announce the next group of negotiated drugs (including Part B) for 2028 by February 2026.
1. Janumet/Janumet XR (Type 2 Diabetes) leads with an 85% discount.
2. Tradjenta (Type 2 Diabetes) follows closely at 84%.
3. Breo Ellipta (Asthma/COPD) has an 83% discount.
4. Linzess (IBS-C) offers 75% savings.
5. Ozempic/Rybelsus/Wegovy (Diabetes/Obesity) comes in at 71%.
